Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Prolactin secretion in benign breast diseases.

R Sitruk-Ware1, F Clair, N Sterkers

  • 1Department of Reproductive Endocrinology, Hôpital Necker, Paris, France.

Gynecological Endocrinology : the Official Journal of the International Society of Gynecological Endocrinology
|June 1, 1987
PubMed
Summary

Benign breast diseases may stem from luteal phase defects, not abnormal prolactin secretion. Studies show no significant prolactin level differences in patients versus controls, suggesting hormonal imbalances are key.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Combined nestorone-testosterone gel suppresses serum gonadotropins to concentrations associated with effective hormonal contraception in men.

Andrology·2019
Same author

Preventing secondary exposure to women from men applying a novel nestorone/testosterone contraceptive gel.

Andrology·2018
Same author

Non-clinical studies of progesterone.

Climacteric : the journal of the International Menopause Society·2018
Same author

Continuous dosing of a novel contraceptive vaginal ring releasing Nestorone® and estradiol: pharmacokinetics from a dose-finding study.

Contraception·2018
Same author

Neurosteroidogenesis and progesterone anti-inflammatory/neuroprotective effects.

Journal of neuroendocrinology·2017
Same author

Impact of various progestins with or without transdermal testosterone on gonadotropin levels for non-invasive hormonal male contraception: a randomized clinical trial.

Andrology·2017

Area of Science:

  • Endocrinology
  • Reproductive Medicine
  • Oncology

Background:

  • Prolactin (PRL) is implicated in benign breast diseases (BBD) pathogenesis.
  • Understanding PRL's role is crucial for BBD etiology.
  • Hormonal fluctuations during the luteal phase may influence BBD.

Purpose of the Study:

  • To evaluate the role of prolactin in benign breast diseases.
  • To compare prolactin levels in BBD patients and healthy controls.
  • To investigate the impact of luteal phase hormonal status on BBD.

Main Methods:

  • Serum prolactin (PRL) levels measured via TRH challenge test in 50 BBD patients and 15 controls.
  • Estradiol (E2) and progesterone (P) levels assessed.
  • Patients subgrouped by BBD type and treated with lynestrenol for 3 months.

Related Experiment Videos

Main Results:

  • No significant differences in basal or TRH-stimulated prolactin secretion between BBD patients and controls.
  • No significant changes observed after lynestrenol treatment.
  • Significantly lower progesterone levels in BBD patients (6.86 +/- 0.9 ng/ml) compared to controls (21.2 +/- 1.4 ng/ml).

Conclusions:

  • Benign breast diseases are not associated with prolactin secretion abnormalities.
  • Inadequate luteal phase, indicated by low progesterone, is more likely linked to BBD.
  • Further research into luteal phase defects in BBD pathogenesis is warranted.